SECsense Logo

InflaRx N.V. Financial Report: $30M Capital Raise via 6-K Filing

$IFRX
Form 6-K
Filed on: 2025-02-18
Source
InflaRx N.V. Financial Report: $30M Capital Raise via 6-K Filing

Here are the key insights extracted from the financial report section provided:

  1. Company Overview:
  • Company Name: InflaRx N.V.
  • Location: Winzerlaer Str. 2, 07745 Jena, Germany.
  1. Filing Information:
  • Form Type: 6-K
  • Commission File Number: 001-38283
  • Filing Date: February 18, 2025
  1. Offering Details:
  • Date of Underwriting Agreement: February 13, 2025.
  • Underwriter: Guggenheim Securities, LLC.
  • Type of Securities Offered:
    • 8,250,000 ordinary shares (Firm Shares) with a nominal value of €0.12 per share.
    • Pre-funded warrants to purchase 6,750,000 ordinary shares.
  • Offering Price: $2.00 per ordinary share; Pre-Funded Warrants are priced at $1.999 per share (exercise price minus $0.001).
  • Closing Date of Offering: February 18, 2025.
  1. Financial Proceeds:
  • Gross Proceeds: Approximately $30 million.
  • Potential Total Proceeds (if the underwriters exercise their option): Approximately $34.5 million.
  • Use of Proceeds: Not specified in the extracted text.
  1. Regulatory Compliance:
  • The offering was made under the effective shelf registration statement on Form F-3 (File No. 333-273058) and a prospectus supplement.
  1. Underwriter Agreements:
  • The Underwriting Agreement includes customary representations and warranties.
  • InflaRx N.V. has agreed to indemnify the underwriters against certain liabilities under the Securities Act of 1933.
  1. Legal Opinions:
  • Legal opinions regarding the legality of the issuance and sale of the shares and warrants have been provided by:
    • NautaDutilh N.V. (Exhibit 5.1)
    • Kirkland & Ellis LLP (Exhibit 5.2)
  1. Incorporation by Reference:
  • This report is incorporated by reference into InflaRx's registration statements on Form S-8 and Form F-3.
  1. Signature:
  • The report is signed by Niels Riedemann, Chief Executive Officer of InflaRx N.V., on February 18, 2025.

This information is significant as it provides insights into the company’s financial activities, specifically the recent capital raise, and outlines the regulatory framework within which the company operates.